Kaiser Permanente- Hawaii

Honolulu, Hawaii 96819

1 studies enrolling now · 15 studies all time

What they study most

Cancer, Cardiovascular Diseases, Carotid Artery Disease, Carotid Artery Stenosis, Diabetes Mellitus, Femoral Artery Occlusion, Femoral Artery Stenosis, General Research Use, Gestational Diabetes, HER2-positive Breast Cancer, Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive, Multiple Myeloma

Studies at this site

• Connect for Cancer Prevention Study (Connect) — Recruiting now
• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer — Running, not enrolling
• A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC — Running, not enrolling
• Glycemic Observation and Metabolic Outcomes in Mothers and Offspring — Completed
• Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease — Completed
• Comparison of Type 2 Diabetes Pharmacotherapy Regimens — Completed
• Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma — Completed
• Selinexor Treatment of Refractory Myeloma — Completed
• A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia — Completed
• The Gore SCAFFOLD Clinical Study — Completed
• A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label — Stopped early
• POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE — Completed
• Hawaii Patient Reward And Incentives to Support Empowerment — Completed
• IN.PACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Superficial Femoral Artery (SFA) and Proximal Popliteal Artery (PPA) — Completed
• TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer — Completed